MetLife Investment Management’s Immunomedics Inc IMMU Stock Holding History

MetLife Investment Management’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-78,858	Closed	-$1.06M	–	2393
2020 Q1	$1.06M	Hold	78,858	–	–	0.01%	879
2019 Q4	$1.67M	Hold	78,858	–	–	0.02%	878
2019 Q3	$1.05M	Hold	78,858	–	–	0.01%	1046
2019 Q2	$1.09M	Buy	78,858 +13,808	+21%	+$208K	0.01%	1065
2019 Q1	$1.25M	Hold	65,050	–	–	0.01%	988
2018 Q4	$928K	Sell	65,050 -10,262	-14%	-$204K	0.01%	1045
2018 Q3	$1.57M	Buy	75,312 +14,897	+25%	+$353K	0.02%	953
2018 Q2	$1.43M	Buy	60,415 +10,612	+21%	+$213K	0.02%	898
2018 Q1	$728K	Hold	49,803	–	–	0.01%	1155
2017 Q4	$805K	Buy	+49,803	New	+$588K	0.01%	1130

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MetLife Investment Management's IMMU Position: Q2 2020 in Review

MetLife Investment Management sold out of Immunomedics Inc (IMMU) in Q2 2020, closing a stake of 78,858 shares — an estimated $1.06M sold.

MetLife Investment Management first reported a position in IMMU in Q4 2017 and held it in 10 quarters. The position peaked at $1.67M in Q4 2019. 313 funds tracked by Wall St. Rank hold IMMU as of Q2 2020.

MetLife Investment Management reported no remaining Immunomedics Inc position as of Q2 2020 after selling out during the quarter.
MetLife Investment Management sold 78,858 Immunomedics Inc shares in Q2 2020, an estimated $1.06M.
MetLife Investment Management first reported a position in Immunomedics Inc in Q4 2017 and held it in 10 quarters.
MetLife Investment Management's Immunomedics Inc position peaked at $1.67M in Q4 2019.
313 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.